8 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $5M | -$10M | 0.0% | -202.1% | -$8M | — | $4M |
| 2024 | $5M | -$8M | 0.0% | -129.2% | — | — | $4M |
| 2023 | $2M | -$11M | 0.0% | -480.5% | — | — | $1M |
| 2022 | $3M | -$24M | 0.0% | -959.9% | — | — | $3M |
| 2021 | $4M | -$29M | 0.0% | -562.7% | — | — | $12M |
| 2020 | — | -$160875 | — | — | — | — | $194214 |
| 2019 | — | -$1M | — | — | — | — | — |
| 2018 | — | $2M | — | — | — | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $960999 | -$4M | 0.0% | -370.7% | — | — | $745482 |
| Dec '25 | $2M | -$3M | 0.0% | -147.8% | -$2M | — | $4M |
| Sep '25 | $493104 | -$4M | 0.0% | -758.7% | — | — | $2M |
| Jun '25 | $1M | -$2M | 0.0% | -127.6% | — | — | $2M |
| Mar '25 | $1M | -$2M | 0.0% | -149.1% | — | — | $3M |
| Dec '24 | $1M | -$4M | 0.0% | -274.3% | — | — | $4M |
| Sep '24 | $3M | $661769 | 0.0% | 18.9% | — | — | $4M |
| Jun '24 | $181797 | -$2M | 0.0% | -1075.6% | — | — | $1M |
| Mar '24 | $305722 | -$3M | 0.0% | -602.8% | — | — | $3M |
| Dec '23 | $515032 | -$4M | 0.0% | -612.7% | — | — | $1M |
| Sep '23 | $435380 | -$3M | 0.0% | -621.8% | — | — | $1M |
| Jun '23 | $490472 | -$2M | 0.0% | -467.7% | — | — | $4M |
| Mar '23 | $789635 | -$2M | 0.0% | -324.4% | — | — | $1M |
| Dec '22 | $1M | -$5M | 0.0% | -432.6% | — | — | $3M |
| Sep '22 | $279351 | -$10M | 0.0% | -2206.3% | — | — | $5M |
| Jun '22 | $207471 | -$8M | 0.0% | -3400.6% | — | — | $4M |
| Mar '22 | $603098 | -$950925 | 0.0% | -796.4% | — | — | $8M |
| Dec '21 | $2M | -$10M | 0.0% | -122.7% | — | — | $12M |
| Sep '21 | $1M | -$17M | 0.0% | -1406.3% | — | — | $7M |
| Jun '21 | $444516 | -$957611 | 0.0% | -92.8% | — | — | $8M |
How the market has priced ENSC against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Ensysce Biosciences, Inc.'s revenue has grown 9.4% per year. These are computed facts, not advice.
As of FY2025, Ensysce Biosciences, Inc. reported — of total debt against $4M of cash; operating income covered interest expense -545.7×.
In FY2025, gross margin was —, operating margin -202.1%, and net margin -200.8%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.